Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Advanced Solid Tumors
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    In order to participate in the study the following conditions must be met:
    1. Patients with advanced solid tumors that have progressed during or after treatment with approved therapies or for which there is no standard effective therapy available.
    2. Recovered from toxicity to prior anti-cancer therapy (ie, to = Grade 1 or had stabilization of the toxic effects of prior anti-cancer therapy). Exceptions: Grade 2 lymphopenia or fatigue are allowed per investigator discretion.
    3. Adequate bone marrow and organ function. Organ function parameters must be assessed within 14 days prior to start of study treatment. Patients must also have no known active or symptomatic central nervous system (CNS) metastases, carcinomatous meningitis, or leptomeningeal disease.

You may not be eligible for this study if the following are true:

  • You will not be able to participate in the study if you have had:
  • Chemotherapy, hormonal (with the exception of ongoing luteinizing hormone-releasing hormone analogs in male patients and premenopausal women), radiation, or biological anti-cancer therapy within 14 days prior to the first dose of study treatment.
  • Have visceral crisis, lymphangitic spread, or leptomeningeal carcinomatosis. Visceral crisis is not the mere presence of visceral metastases but implies severe organ dysfunction as assessed by symptoms and signs, laboratory studies, and rapid disease progression.
  • Received treatment with an investigational agent for any indication within 14 days for non-myelosuppressive agent or 21 days or < 5 half-lives, whichever is longer, for myelosuppressive agent prior to the first dose of study treatment.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.